CAJ | 학술논문

目的探讨微小RNA(miR)-129在胃癌组织中的表达及临床意义,并评估其在两种含铂化疗方案治疗晚期胃癌患者的价值.方法检测52例胃癌患者福马林固定后石蜡包埋(FFPE)肿瘤组织及11例正常胃组织中miR-129的表达水平,并结合临床病理资料进行分析.结果 miR-129在胃癌组织中表达水平显著高于正常胃组织(P ＜0.01);miR-129的表达水平与既往治疗史比较差异有统计学意义(P＜0.05).两个疗程后的疗效与晚期胃癌患者总生存时间明显相关,疗效为部分缓解(PR)、稳定(SD)、疾病进展(PD)的患者中位生存时间分别为8.41(5.29～11.52)、10.16(7.19～13.14)和5.10(3.11～7.08)个月.miR-129高表达患者与低表达患者中位生存时间分别为6.27(5.17 ～7.37)、8.74(6.71 ～10.77)个月,差异有统计学意义(P＜0.05).miR-129高表达胃癌患者死亡风险比(HR)为miR-129低表达胃癌患者的2.77倍[95％可信区间(CI):1.12～6.87,P＜0.05];SD、PD患者的HR分别为PR患者的0.95(95％CI:0.351 ～2.562,P＞0.05)和6.02倍(95％CI:1.683 ～21.570,P＜0.01).结论胃癌组织中miR-129异常表达,其表达水平与晚期胃癌患者预后显著相关.
목적 탐토미소RNA(miR)-129재위암조직중적표체급림상의의,병평고기재량충함박화료방안치료만기위암환자적개치.방법 검측52례위암환자복마림고정후석사포매(FFPE)종류조직급11례정상위조직중miR-129적표체수평,병결합림상병리자료진행분석.결과 miR-129재위암조직중표체수평현저고우정상위조직(P ＜0.01);miR-129적표체수평여기왕치료사비교차이유통계학의의(P＜0.05).량개료정후적료효여만기위암환자총생존시간명현상관,료효위부분완해(PR)、은정(SD)、질병진전(PD)적환자중위생존시간분별위8.41(5.29～11.52)、10.16(7.19～13.14)화5.10(3.11～7.08)개월.miR-129고표체환자여저표체환자중위생존시간분별위6.27(5.17 ～7.37)、8.74(6.71 ～10.77)개월,차이유통계학의의(P＜0.05).miR-129고표체위암환자사망풍험비(HR)위miR-129저표체위암환자적2.77배[95％가신구간(CI):1.12～6.87,P＜0.05];SD、PD환자적HR분별위PR환자적0.95(95％CI:0.351 ～2.562,P＞0.05)화6.02배(95％CI:1.683 ～21.570,P＜0.01).결론 위암조직중miR-129이상표체,기표체수평여만기위암환자예후현저상관.
Objective To explore the microRNA (miR)-129 expression and its clinical significance in advanced gastric cancer,to evaluate the effectiveness of S-1/oxaliplatin vs.doxifluridine/oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in patients with advanced gastric cancer.Methods Total RNAs were extracted from normal and gastric tumor formalinfixed,paraffin embedded (FFPE) specimens.miR-129 expression was quantified using real-time quantitative polymerase chain reaction (real-time PCR) analysis.The correlation between the expression levels of miR-129 with clinical characteristics was analyzed by using chi-square test.Overall survival (OS) in patients with clinicopathological characteristics was analyzed using Kaplan-Meier and Log-rank test.The Cox proportional hazards model was performed to estimate Hazard risk (HR) with 95％ confidence interval (CI) of the linking strength between the different clinical characteristics,the expression of miR-129,and death risk.Results The expression levels of miR-129 were significantly up-regulated in gastric tumors compared to normal gastric tissues (P ＜ 0.01),and were significantly correlated with the previous treatment (P ＜ 0.05),but not with gender,age,stage,tumor size and histological type by using Chi-square test.After two-course treatment,therapeutic effectiveness was significantly correlated with OS (P ＜ 0.05),and Kaplan-Meier survival analysis revealed that the median survival time in patients with PR,SD and PD was 8.41 (5.29-11.52),10.16 (7.19-13.14) and 5.10 (3.11-7.08) months respectively.The up-regulation of the miR-129 expression was closely associated with shorter OS.The median OS in patient with low expression of miR-129 was 8.74 (6.71-10.77) months.In contrast,the median OS was only 6.27 (5.17-7.37)months in patients with the high expression of miR-129 (P ＜ 0.05).The results of Cox model showed that the HR of patients SD,and PD was 0.95 (95％ CI:0.351-2.562,P ＞0.05) and 6.02 (95％ CI:1.683-21.570,P ＜0.0l) as compared with PR patients.The median survival time in patients with low miR-129expression was significantly prolonged as compared with that in patients with high miR-129 expression [8.74 (6.71-10.77) and 6.27 (5.17-7.37),respectively].The HR for death risk in stomach carcinoma patients with high miR-129 expression was 2.77 times higher than in those with low miR-129 expression (95％ CI:1.12-6.87,P ＜ 0.05).Conclusion Abnormal expression of miR-129 has been implicated in gastric cancer,and the expression level of miR-129 was closely associated with prognosis of advanced gastric cancer patients.miR-129 holds great potential as a prognostic biomarker and a valuable indicator of chemotherapy regimen in gastric cancer.